High serum biotin concentrations in patients taking biotin supplements may cause an interference in this assay. Patients may be advised to stop biotin consumption at least 72 hours prior to sample collection.

Gold serum separator (SST) tube

OR

Red serum vial/tube, 5 mL

Immediatley following collection, mix sample by gently inverting 5 times

1. Allow sample to clot for a minimum of 30 minutes
2. Spin within two (2) hours of sample collection
3. Transfer serum to a Screw-cap polypropylene frozen transport vial/tube - 4mL (LabCorp), labelled as serum
4. Freeze

Screw-cap polypropylene frozen transport vial/tube - 4mL (LabCorp)

Dk green heparin (Li or Na), no gel

Immediatley following collection, mix sample thoroughly by gentle inverting 8 - 10 times, to prevent clotting

1. Spin within two (2) hours of sample collection
2. Transfer serum to a Screw-cap polypropylene frozen transport vial/tube - 4mL (LabCorp), labelled as appropriate plasma type
3. Freeze

Frozen (preferred) - 359 days

Freeze/thaw cycle: stable x6

Refrigerated - 7 days

Ambient - 7 days

Freeze/thaw cylces - stable x6

Electrochemiluminescence Immunoassay (ECLIA)

An interpretive report will be provided

In the absence of anti-infliximab antibodies, the infliximab drug level typically reflects the total infliximab concentration in serum. In the presence of anti-infliximab antibodies, the infliximab drug level typically reflects the antibody-unbound fraction of infliximab concentration in serum.

The presence of infliximab drug, even at concentrations well above target treatment levels (>50 ug/mL), does not interfere with the anti-infliximab antibody detection. This assay may be helpful for any patients on infliximab therapy for diseases such as Crohn's disease, inflammatory bowel disease, ulcerative colitis, rhematoid arthritis, or other autoimmune conditions. This test includes long-term serial monitoring of results.